Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo do patritumab deRuxtecan Plus Pembrolizumab com outros agentes anticâncer em participantes com câncer de mama negativo de receptor triplo e hormonal-baixo/Herthena-Breast-03)/HER-2 (MK-1022-010, Herthena-Breast-03)

11 de novembro de 2026 atualizado por: Merck Sharp & Dohme LLC

Um estudo de fase 2 randomizado de etiqueta aberta para avaliar a segurança e a eficácia do patritumab deRuxtecan mais pembrolizumab administrado antes ou após a carboplatina/paclitaxel mais pembrolizumab em comparação com o pimbrolizumab em combinação com quimioterapia seguida por correção e triturão adjumol Receptor negativo ou hormonal-baixo positivo/humano Fator de crescimento epidérmico Câncer de mama negativo (Herthena-Breast03)

Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn:

  • About the safety of the study treatments and if people tolerate them
  • If people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (pembro) and chemotherapy.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

372

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Seoul, Coréia do Sul, 03080
        • Recrutamento
        • Seoul National University Hospital ( Site 2400)
        • Contato:
          • Study Coordinator
          • Número de telefone: +82220720850
      • Seoul, Coréia do Sul, 05505
        • Recrutamento
        • Asan Medical Center ( Site 2401)
        • Contato:
          • Study Coordinator
          • Número de telefone: +82230103217
      • Seoul, Coréia do Sul, 03722
        • Recrutamento
        • Severance Hospital, Yonsei University Health System ( Site 2402)
        • Contato:
          • Study Coordinator
          • Número de telefone: +82222288135
      • Córdoba, Espanha, 14004
        • Recrutamento
        • Hospital Universitario Reina Sofia ( Site 1702)
        • Contato:
          • Study Coordinator
          • Número de telefone: +34 957012408
    • Catalonia
      • Badalona, Catalonia, Espanha, 08916
        • Recrutamento
        • Institut Català d'Oncologia (ICO) - Badalona ( Site 1700)
        • Contato:
          • Study Coordinator
          • Número de telefone: +34934978925
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Espanha, 28027
        • Recrutamento
        • Clinica Universidad de Navarra ( Site 1703)
        • Contato:
          • Study Coordinator
          • Número de telefone: +34913531920
    • California
      • Santa Monica, California, Estados Unidos, 90404
        • Recrutamento
        • UCLA Hematology/Oncology - Parkside ( Site 0021)
        • Contato:
          • Study Coordinator
          • Número de telefone: 424-402-9520
    • Illinois
      • Skokie, Illinois, Estados Unidos, 60077
        • Recrutamento
        • Orchard Healthcare Research Inc. ( Site 0006)
        • Contato:
          • Study Coordinator
          • Número de telefone: 847-568-9932
    • Montana
      • Billings, Montana, Estados Unidos, 59102
        • Recrutamento
        • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003)
        • Contato:
          • Study Coordinator
          • Número de telefone: 406-238-6685
    • Oregon
      • Happy Valley, Oregon, Estados Unidos, 97015
        • Recrutamento
        • Northwest Cancer Specialists, P.C. ( Site 8003)
        • Contato:
          • Study Coordinator
          • Número de telefone: 360-944-9889
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37203
        • Recrutamento
        • SCRI Oncology Partners ( Site 7000)
        • Contato:
          • Study Coordinator
          • Número de telefone: 844-482-4812
    • Texas
      • Dallas, Texas, Estados Unidos, 75246
        • Recrutamento
        • Texas Oncology - DFW ( Site 8000)
        • Contato:
          • Study Coordinator
          • Número de telefone: 214-370-1067
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • Houston Methodist Hospital ( Site 0022)
        • Contato:
          • Study Coordinator
          • Número de telefone: 713-441-9948
    • Virginia
      • Norfolk, Virginia, Estados Unidos, 23502
        • Recrutamento
        • Virginia Oncology Associates (VOA) ( Site 8001)
        • Contato:
          • Study Coordinator
          • Número de telefone: 844-482-4812
      • Taichung, Taiwan, 407
        • Recrutamento
        • Taichung Veterans General Hospital ( Site 2502)
        • Contato:
          • Study Coordinator
          • Número de telefone: +886423592525
      • Tainan, Taiwan, 704
        • Recrutamento
        • National Cheng Kung University Hospital ( Site 2503)
        • Contato:
          • Study Coordinator
          • Número de telefone: +88662353535
      • Taipei, Taiwan, 112
        • Recrutamento
        • Koo Foundation Sun Yat-Sen Cancer Center ( Site 2501)
        • Contato:
          • Study Coordinator
          • Número de telefone: 886228970011x1686

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has locally advanced, non-metastatic (M0), breast cancer, defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per current American Joint Committee on Cancer (AJCC) criteria: cT1c, N1-N2; cT2, N0-N2; cT3, N0-N2; or cT4a-d, N0-N2
  • Has centrally confirmed diagnosis of breast cancer that is triple-negative or HR-low+/HER2- breast cancer that will be treated according to the triple-negative breast cancer (TNBC) paradigm
  • Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
  • Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 28 days prior to allocation/randomization
  • Has left ventricular ejection fraction (LVEF) of ≥50% or ≥ lower limit of normal (LLN) as assessed by echocardiogram (ECHO) or multigate acquisition scan (MUGA) scan

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has uncontrolled or significant cardiovascular disease before randomization
  • Has any history of or evidence of any current leptomeningeal carcinomatosis.
  • Has clinically significant corneal disease
  • Has human immunodeficiency virus (HIV) infection with a history of Kaposi sarcoma and/or multicentric Castleman disease
  • Has evidence of ongoing, uncontrolled, systemic bacterial, fungal, or viral infection
  • Has received prior therapy with an anti-programmed death (PD)-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor
  • Has received any prior treatment, including radiation, systemic therapy, and/or definitive surgery for currently diagnosed breast cancer
  • Has received prior treatment with an anti-human epidermal growth factor receptor 3 (HER3) antibody and/or antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., trastuzumab deruxtecan)
  • Has metastatic (Stage IV) breast cancer or cN3 nodal involvement
  • Has known additional malignancy that is progressing or has required active treatment within the past 5 years
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current or suspected ILD
  • Has an active infection requiring systemic therapy
  • Has concurrent active HBV and HCV infection
  • Has clinically severe respiratory compromise resulting from intercurrent pulmonary illness

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Part 1, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin

In Part 1, participants receive neoadjuvant pembrolizumab 200 mg via intravenous (IV) infusion every 3 weeks (Q3W) plus patritumab deruxtecan via IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg via IV infusion Q3W plus paclitaxel 80 mg/m^2 via IV infusion every week (QW) and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer.

Administered via IV infusion as neoadjuvant treatment

Outros nomes:
  • U3-1402
  • HER3-DXd
  • MK-1022

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

Outros nomes:
  • MK-3475
  • KEYTRUDA®

Administered via IV infusion as neoadjuvant treatment

Outros nomes:
  • TAXOL®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

Outros nomes:
  • PARAPLATIN®
Experimental: Part 2, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin

In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion every Q3W plus patritumab deruxtecan (dose to be determined in part 1) IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks. At 3-6 weeks after last dose of neoadjuvant treatment, participants undergo surgery for breast cancer. After surgery, participants receive adjuvant pembrolizumab 400 mg IV every 6 weeks (Q6W) for ~30 weeks. Additional adjuvant treatment of physician's choice (TPC) may be given to participants with residual disease. TPC options are olaparib 300 mg oral twice daily (BID) for 1 year (participants with germline BRCA mutation [gBRCAm] only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV Q3W or every 2 weeks (Q2W) and cyclophosphamide 600 mg/m^2 IV Q3W or Q2W for 4 doses.

Administered via IV infusion as neoadjuvant treatment

Outros nomes:
  • U3-1402
  • HER3-DXd
  • MK-1022

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

Outros nomes:
  • MK-3475
  • KEYTRUDA®

Administered via IV infusion as neoadjuvant treatment

Outros nomes:
  • TAXOL®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

Outros nomes:
  • PARAPLATIN®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Outros nomes:
  • ADRIAMICINA®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Outros nomes:
  • ELLENCE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Outros nomes:
  • CYTOXAN®

Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2

Outros nomes:
  • XELODA®

Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2

Outros nomes:
  • LYNPARZA®
Experimental: Part 2, B: Pembrolizumab + paclitaxel + carboplatin → Pembrolizumab + patritumab deruxtecan

In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus patritumab deruxtecan (dose to be determined in part 1) via IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for ~30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W or Q2W and cyclophosphamide 600 mg/m^2 IV infusion Q3W or Q2W for 4 doses.

Administered via IV infusion as neoadjuvant treatment

Outros nomes:
  • U3-1402
  • HER3-DXd
  • MK-1022

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

Outros nomes:
  • MK-3475
  • KEYTRUDA®

Administered via IV infusion as neoadjuvant treatment

Outros nomes:
  • TAXOL®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

Outros nomes:
  • PARAPLATIN®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Outros nomes:
  • ADRIAMICINA®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Outros nomes:
  • ELLENCE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Outros nomes:
  • CYTOXAN®

Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2

Outros nomes:
  • XELODA®

Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2

Outros nomes:
  • LYNPARZA®
Comparador Ativo: Part 2, C: Pembro + paclitaxel + carboplatin→ Pembro + doxorubicin (or epirubicin) +cyclophosphamide

In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W and cyclophosphamide 600 mg/m^2 IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for approximately 30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only) or capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles.

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

Outros nomes:
  • MK-3475
  • KEYTRUDA®

Administered via IV infusion as neoadjuvant treatment

Outros nomes:
  • TAXOL®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

Outros nomes:
  • PARAPLATIN®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Outros nomes:
  • ADRIAMICINA®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Outros nomes:
  • ELLENCE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Outros nomes:
  • CYTOXAN®

Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2

Outros nomes:
  • XELODA®

Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2

Outros nomes:
  • LYNPARZA®

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Part 1: Number of Participants Experiencing an Adverse Event (AE)
Prazo: Up to ~43 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 1.

Up to ~43 weeks
Part 1: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)
Prazo: Up to 21 days

A DLT is defined by the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) Version 5.0, assessed by investigator as drug-related: Grade (gr) 3 or 4 nonhematologic toxicity (with exceptions); gr 3 or gr 4 laboratory values (with exceptions); gr 3 or 4 febrile neutropenia; prolonged delay (>2 weeks) in initiating Cycle 2 (cycle length = 3 weeks) due to intervention-related toxicity; any intervention-related toxicity that causes the participant to discontinue intervention during Cycle 1; interstitial lung disease as per investigator; any other gr ≥3 pulmonary toxicity; or gr 5 toxicity.

Up to 21 days
Part 1: Number of Participants who Discontinued Study Treatment Due to an AE
Prazo: Up to ~30 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 1.

Up to ~30 weeks
Part 2: Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0
Prazo: Up to ~30 weeks

pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery.

Up to ~30 weeks
Part 2: Number of Participants Experiencing an AE
Prazo: Up to ~103 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 2.

Up to ~103 weeks
Part 2: Number of Participants who Discontinued Study Treatment Due to an AE
Prazo: Up to ~90 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 2.

Up to ~90 weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Part 2: pCR-No Ductal Carcinoma in Situ (DCIS) Rate Using the Definition of ypT0 ypN0
Prazo: Up to ~30 weeks

pCR-no DCIS (ypT0 ypN0) is defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery.

Up to ~30 weeks
Part 2: Event-Free Survival (EFS)
Prazo: Up to ~100 months

EFS is defined as the time from randomization to disease progression that precludes surgery, local or distant recurrence, or death due to any cause, whichever occurs first.

Up to ~100 months
Part 2: Overall Survival (OS)
Prazo: Up to ~100 months

OS is defined as the time from randomization to date of death due to any cause.

Up to ~100 months
Part 2: Distant Progression or Distant Recurrence-Free Survival (DPDRFS)
Prazo: Up to ~100 months

DPDRFS is defined as the time from randomization to first distant progression or distant recurrence event as assessed or death due to any cause, whichever occurs first.

Up to ~100 months
Part 2: Residual Cancer Burden (RCB)
Prazo: Up to ~30 weeks

RCB is defined as residual disease in either the breast or lymph node at the time of surgery. RCB score provides a continuous measurement of the extent of residual cancer. There are four RCB classes: RCB-0 (RCB score 0), RCB-1 (0< RCB score <1.36), RCB-2 (1.36 <RCB score <3.28), and RCB-3 (RCB score >3.28).

Up to ~30 weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Diretor de estudo: Medical Director, Merck Sharp & Dohme LLC

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

20 de março de 2025

Conclusão Primária (Estimado)

31 de dezembro de 2029

Conclusão do estudo (Estimado)

16 de março de 2031

Datas de inscrição no estudo

Enviado pela primeira vez

21 de janeiro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

21 de janeiro de 2025

Primeira postagem (Real)

28 de janeiro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

11 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 1022-010
  • MK-1022-010 (Outro identificador: MSD)
  • U1111-1307-7867 (Identificador de registro: UTN)
  • 2024-514376-40-00 (Identificador de registro: EU CT)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .